Twist Bioscience Corp vs United States Natural Gas Fund — how do they compare? Twist Bioscience Corp trades at $160.94 (market cap $10.08B), while United States Natural Gas Fund trades at $11.01 (market cap $517.27M). The key difference: Twist Bioscience Corp is far larger — about 19.5× United States Natural Gas Fund's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and United States Natural Gas Fund for 22 Days on average.
| TWST | UNG | |
|---|---|---|
Market Cap | $10.08B | $517.27M |
Volume | 4,229,037 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $205.00 | $16.90 |
52-Week Low | $25.45 | $9.63 |
Typical Hold Time | 27 Days | 22 Days |
Enterprise Value | $10.01B | — |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
UNG trades at $11.10, up 0.63% with a bullish technical signal from moving averages. The fund shows strong profitability with $65.15M net income for 2024, though revenue remains at $0.00. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy prices. The fund maintains a solid balance sheet with $594.68M in current assets and minimal liabilities.
Investment outlook remains cautiously optimistic given bullish technical indicators and strong profitability metrics. Key risks include natural gas price volatility and geopolitical factors affecting energy markets. The absence of traditional valuation metrics requires careful monitoring of underlying commodity trends for informed positioning.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →